| |
| |
|
| Insider
Information: |
Sachdev Amit |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
71,325 |
|
|
Indirect Shares
|
7,447 |
|
|
| Direct
Value |
$24,204,134 |
|
|
|
Indirect Value
|
$3,257,988 |
|
|
| Total
Shares |
78,772 |
|
|
| Total
Value |
$27,462,122 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-02-26 |
55,325 |
2024-02-26 |
7,447 |
Premium* |
|
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
192 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CLDN |
Celladon Corp |
|
• • – |
2022-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,000 |
0 |
- |
|
| CLDN |
Celladon Corp |
Director |
– • – |
2020-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| CLDN |
Celladon Corp |
Director |
– • – |
2021-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2023-11-15 |
4 |
AS |
$369.92 |
$12,947 |
D/D |
(35) |
58,814 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,680 |
72,494 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,114 |
79,608 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-09 |
4 |
D |
$422.74 |
$854,780 |
D/D |
(2,022) |
77,586 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-12 |
4 |
AS |
$420.24 |
$1,354,013 |
D/D |
(3,222) |
74,364 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-16 |
4 |
D |
$424.01 |
$1,483,187 |
D/D |
(3,498) |
70,866 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-20 |
4 |
D |
$420.58 |
$1,103,181 |
D/D |
(2,623) |
68,243 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-20 |
4 |
AS |
$420.79 |
$1,790,041 |
D/D |
(4,254) |
63,989 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-21 |
4 |
AS |
$421.77 |
$1,345,868 |
D/D |
(3,191) |
60,798 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-23 |
4 |
D |
$431.79 |
$1,066,090 |
D/D |
(2,469) |
58,329 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
• – – |
2024-02-26 |
4 |
AS |
$425.70 |
$1,278,803 |
D/D |
(3,004) |
55,325 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-22 |
4 |
OE |
$86.52 |
$335,957 |
D/D |
3,883 |
37,299 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-22 |
4 |
AS |
$190.27 |
$738,818 |
D/D |
(3,883) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
AS |
$195.01 |
$840,688 |
D/D |
(4,311) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-10-25 |
4 |
OE |
$91.05 |
$392,517 |
D/D |
4,311 |
37,727 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$364,235 |
D/D |
4,097 |
37,513 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-04 |
4 |
AS |
$199.77 |
$820,795 |
D/D |
(4,097) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-15 |
4 |
AS |
$205.95 |
$11,739 |
D/D |
(57) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-25 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-11-25 |
4 |
AS |
$220.00 |
$1,100,000 |
D/D |
(5,000) |
33,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
AS |
$225.00 |
$1,125,000 |
D/D |
(5,000) |
33,416 |
0 |
- |
|
192 Records found
|
|
Page 1 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
